Page 8 - Carrie Bourdow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences
CHESTERBROOK, Pa., Jan. 07, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences, with additional details below.
 
 
 
 
 
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment ....

Bob Yoder , Hc Wainwright Bioconnect , Carrie Bourdow , Exchange Commission , Company Annual Report On Form , Lifesci Advisors , Trevena Inc , Company Contact , Panel Discussion , Sci Partners , Annual Healthcare Corporate Access , Successful Product Launch During , Senior Vice President , Chief Commercial , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Quarterly Reports , Dan Ferry Managing Director Lifesci Advisors , Chief Commercial Officer Trevena , பாப் யோடர் , பரிமாற்றம் தரகு , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , திரேவென இன்க் , நிறுவனம் தொடர்பு , குழு கலந்துரையாடல் ,